← Back to Screener
Agenus Inc. (AGEN)
Price$4.64
Favorite Metrics
Price vs S&P 500 (26W)11.84%
Price vs S&P 500 (4W)22.64%
Market Capitalization$179.93M
P/E Ratio (Annual)1564.58x
All Metrics
Book Value / Share (Quarterly)$0.24
P/TBV (Annual)31.87x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.22%
Cash Flow / Share (Quarterly)$-2.19
Price vs S&P 500 (YTD)51.18%
Gross Margin (TTM)99.11%
Net Profit Margin (TTM)0.10%
EPS (TTM)$-0.39
10-Day Avg Trading Volume1.45M
EPS Excl Extra (TTM)$-0.39
Revenue Growth (5Y)5.31%
EPS (Annual)$0.00
ROI (Annual)-49.19%
Gross Margin (Annual)99.11%
Net Profit Margin (5Y Avg)-121.87%
Cash / Share (Quarterly)$0.08
P/E Basic Excl Extra (TTM)1564.58x
Revenue Growth QoQ (YoY)27.45%
P/E Normalized (Annual)1564.58x
ROA (Last FY)0.05%
Revenue Growth TTM (YoY)10.37%
EBITD / Share (TTM)$2.94
ROE (5Y Avg)-132.67%
Operating Margin (TTM)70.54%
Cash Flow / Share (Annual)$-2.19
P/B Ratio52.67x
P/B Ratio (Quarterly)153.49x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.38x
Net Interest Coverage (TTM)0.96x
ROA (TTM)0.05%
EV / EBITDA (TTM)5.68x
EPS Incl Extra (Annual)$0.00
Current Ratio (Annual)0.41x
Quick Ratio (Quarterly)0.41x
3-Month Avg Trading Volume0.72M
52-Week Price Return171.35%
P/E Incl Extra (TTM)1564.58x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.60
P/S Ratio (Annual)1.58x
Asset Turnover (Annual)0.50x
52-Week High$7.34
Operating Margin (5Y Avg)-64.44%
EPS Excl Extra (Annual)$0.00
CapEx CAGR (5Y)-71.97%
Tangible BV CAGR (5Y)-23.22%
26-Week Price Return15.83%
Quick Ratio (Annual)0.41x
13-Week Price Return13.65%
Total Debt / Equity (Annual)0.41x
Current Ratio (Quarterly)0.41x
Enterprise Value$500.669
Revenue / Share Growth (5Y)-17.78%
Asset Turnover (TTM)0.54x
Book Value / Share Growth (5Y)-61.57%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-2.70%
Cash / Share (Annual)$0.08
3-Month Return Std Dev100.12%
Gross Margin (5Y Avg)96.94%
Net Income / Employee (TTM)$0
ROE (Last FY)-69.47%
Net Interest Coverage (Annual)0.96x
EPS Basic Excl Extra (Annual)$0.00
P/FCF (TTM)1.65x
Receivables Turnover (TTM)102.05x
Total Debt / Equity (Quarterly)4.01x
EPS Incl Extra (TTM)$-0.39
Receivables Turnover (Annual)102.05x
ROI (TTM)48.69%
P/S Ratio (TTM)1.58x
Pretax Margin (5Y Avg)-127.38%
Revenue / Share (Annual)$3.84
Tangible BV / Share (Annual)$2.02
Forward P/E3.57x
Price vs S&P 500 (52W)141.52%
P/E Ratio (TTM)1564.58x
Year-to-Date Return53.82%
5-Day Price Return8.54%
EPS Normalized (Annual)$0.00
ROA (5Y Avg)-47.40%
Net Profit Margin (Annual)0.10%
Month-to-Date Return44.61%
Cash Flow / Share (TTM)$-0.81
EBITD / Share (Annual)$2.96
Operating Margin (Annual)70.54%
LT Debt / Equity (Annual)0.37x
ROI (5Y Avg)-75.46%
P/E Excl Extra (TTM)1564.58x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.39
P/TBV (Quarterly)79.78x
P/B Ratio (Annual)24.02x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-2.70%
Book Value / Share (Annual)$2.68
Price vs S&P 500 (13W)12.96%
Beta1.79x
P/FCF (Annual)197.72x
Revenue / Share (TTM)$3.32
ROE (TTM)76.63%
52-Week Low$1.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AGENAgenus Inc. | 1.58x | 10.37% | 99.11% | — | $4.64 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Agenus is a clinical-stage immunotherapy company developing therapies to activate the immune system against cancer and infectious disease. Its pipeline includes immune-modulatory antibodies (botensilimab, a CTLA-4 inhibitor; balstilimab, a PD-1 inhibitor), adoptive cell therapies through subsidiary MiNK Therapeutics, and vaccine adjuvants via subsidiary SaponiQx. The company operates in-house cGMP manufacturing and clinical operations capabilities to support product development.